Sections
Excerpt
Relatively few significant advances have occurred in the pharmacological management of eating disorders in recent years. In patients with anorexia nervosa (AN), pharmacotherapy studies have failed to find significant benefit across several medication classes and numerous controlled trials. Currently, no evidence-based pharmacological recommendations can be made for the treatment of AN. In bulimia nervosa (BN), pharmacotherapy trials have been more positive, and fluoxetine has been approved by the U.S. Food and Drug Administration (FDA) for this indication. Additional research on combination pharmacotherapy and aug-mentation strategies for treating partial responders and nonresponders to medications also should be considered. In binge-eating disorder (BED), medications from numerous classes have resulted in reductions in binge-eating frequency. Few trials, however, have resulted in meaningful weight loss, which is generally desired by BED patients who seek treatment. Additional research is needed in the pharmacotherapy of all of the eating disorders, especially the pharmacological treatment of AN.
Access content
To read the fulltext, please use one of the options below to sign in or purchase access.- Personal login
- Institutional Login
- Sign in via OpenAthens
- Register for access
-
Please login/register if you wish to pair your device and check access availability.
Not a subscriber?
PsychiatryOnline subscription options offer access to the DSM-5 library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.
Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).
